Robert Azelby Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Robert Azelby.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Robert Azelby. Robert Azelby is Director in IMMUNOMEDICS INC ($IMMU) and Director in Cascadian Therapeutics, Inc. ($CASC) and President and CEO in ALDER BIOPHARMACEUTICALS INC ($ALDR) and Director in Clovis Oncology, Inc. ($CLVS) and EVP & Chief Commercial Officer in Juno Therapeutics, Inc. ($JUNO) and See Remarks in Juno Therapeutics, Inc. ($JUNO).
Latest Insider Trading Transactions of Robert Azelby
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ALDR, CASC, CLVS, IMMU, JUNO
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 11 2021 | CLVS | Clovis Oncology, I ... | Azelby Robert | Director | Option Exercise | A | 5.97 | 42,223 | 252,071 | 42,223 | |
| Jun 22 2020 | IMMU | IMMUNOMEDICS INC | Azelby Robert | Director | Option Exercise | A | 33.62 | 6,540 | 219,875 | 6,540 | |
| Jun 22 2020 | IMMU | IMMUNOMEDICS INC | Azelby Robert | Director | Grant | A | 0.00 | 3,718 | 0 | 3,718 | 0 to 3.7 K |
| Jun 05 2020 | CLVS | Clovis Oncology, I ... | Azelby Robert | Director | Option Exercise | A | 6.48 | 40,138 | 260,094 | 40,138 | |
| Feb 27 2020 | IMMU | IMMUNOMEDICS INC | Azelby Robert | Director | Option Exercise | A | 16.36 | 22,500 | 368,100 | 22,500 | |
| Oct 24 2019 | ALDR | ALDER BIOPHARMACEU ... | Azelby Robert | President and CEO | Option Exercise | D | 16.20 | 150,000 | 2,430,000 | 0 | |
| Oct 24 2019 | ALDR | ALDER BIOPHARMACEU ... | Azelby Robert | President and CEO | Option Exercise | D | 0.00 | 15,000 | 0 | 0 | |
| Oct 24 2019 | ALDR | ALDER BIOPHARMACEU ... | Azelby Robert | President and CEO | Option Exercise | D | 14.00 | 505,000 | 7,070,000 | 0 | |
| Oct 24 2019 | ALDR | ALDER BIOPHARMACEU ... | Azelby Robert | President and CEO | Option Exercise | D | 16.20 | 1,000,000 | 16,200,000 | 0 | |
| Jun 07 2019 | CLVS | Clovis Oncology, I ... | Azelby Robert | Director | Option Exercise | A | 14.66 | 28,882 | 423,410 | 28,882 | |
| Jun 07 2019 | CLVS | Clovis Oncology, I ... | Azelby Robert | Director | Option Exercise | A | 14.66 | 28,882 | 423,410 | 28,882 | |
| Apr 25 2019 | ALDR | ALDER BIOPHARMACEU ... | Azelby Robert | President and CEO | Option Exercise | A | 16.20 | 150,000 | 2,430,000 | 150,000 | |
| Feb 08 2019 | ALDR | ALDER BIOPHARMACEU ... | Azelby Robert | President and CEO | Option Exercise | A | 0.00 | 15,000 | 0 | 15,000 | |
| Feb 08 2019 | ALDR | ALDER BIOPHARMACEU ... | Azelby Robert | President and CEO | Option Exercise | A | 14.00 | 505,000 | 7,070,000 | 505,000 | |
| Oct 15 2018 | CLVS | Clovis Oncology, I ... | Azelby Robert | Director | Option Exercise | A | 27.92 | 25,848 | 721,676 | 25,848 | |
| Oct 15 2018 | CLVS | Clovis Oncology, I ... | Azelby Robert | Director | Option Exercise | A | 27.92 | 25,848 | 721,676 | 25,848 | |
| Jun 15 2018 | ALDR | ALDER BIOPHARMACEU ... | Azelby Robert | President and CEO | Option Exercise | A | 16.20 | 1,000,000 | 16,200,000 | 1,000,000 | |
| Mar 13 2018 | CASC | Cascadian Therapeu ... | Azelby Robert | Director | Option Exercise | D | 0.00 | 13,927 | 0 | 0 | |
| Mar 13 2018 | CASC | Cascadian Therapeu ... | Azelby Robert | Director | Option Exercise | D | 0.00 | 12,437 | 0 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | D | 20.76 | 98,545 | 2,045,794 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | D | 25.29 | 30,002 | 758,751 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | D | 51.76 | 93,294 | 4,828,897 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | D | 0.00 | 35,893 | 0 | 0 | 35.9 K to 0 (-100.00 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | D | 0.00 | 25,639 | 0 | 35,893 | 61.5 K to 35.9 K (-41.67 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | D | 0.00 | 20,580 | 0 | 61,532 | 82.1 K to 61.5 K (-25.06 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | D | 0.00 | 7,500 | 0 | 82,112 | 89.6 K to 82.1 K (-8.37 %) |
| Feb 14 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 85.55 | 4,157 | 355,631 | 89,614 | 93.8 K to 89.6 K (-4.43 %) |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 20.76 | 2,663 | 55,284 | 98,545 | |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 25.29 | 834 | 21,092 | 30,002 | |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 85.77 | 3,497 | 299,938 | 93,771 | 97.3 K to 93.8 K (-3.60 %) |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 20.76 | 2,663 | 55,284 | 97,268 | 94.6 K to 97.3 K (+2.81 %) |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 25.29 | 834 | 21,092 | 94,605 | 93.8 K to 94.6 K (+0.89 %) |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Payment of Exercise | F | 85.49 | 2,700 | 230,823 | 93,771 | 96.5 K to 93.8 K (-2.80 %) |
| Feb 02 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 51.76 | 4,167 | 215,684 | 93,294 | |
| Feb 02 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 85.78 | 4,167 | 357,445 | 96,471 | 100.6 K to 96.5 K (-4.14 %) |
| Feb 02 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 51.76 | 4,167 | 215,684 | 100,638 | 96.5 K to 100.6 K (+4.32 %) |
| Feb 02 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Grant | A | 0.00 | 25,639 | 0 | 96,471 | 70.8 K to 96.5 K (+36.20 %) |
| Jan 24 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 51.76 | 102,539 | 5,307,419 | 97,461 | |
| Jan 24 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 86.25 | 102,539 | 8,843,989 | 70,832 | 173.4 K to 70.8 K (-59.14 %) |
| Jan 24 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 51.76 | 102,539 | 5,307,419 | 173,371 | 70.8 K to 173.4 K (+144.76 %) |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 20.76 | 26,633 | 552,901 | 101,208 | |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 25.29 | 2,498 | 63,174 | 30,836 | |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 69.95 | 7,990 | 558,901 | 70,832 | 78.8 K to 70.8 K (-10.14 %) |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 68.10 | 21,141 | 1,439,702 | 78,822 | 100 K to 78.8 K (-21.15 %) |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 20.76 | 26,633 | 552,901 | 99,963 | 73.3 K to 100 K (+36.32 %) |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 25.29 | 2,498 | 63,174 | 73,330 | 70.8 K to 73.3 K (+3.53 %) |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 20.76 | 26,633 | 552,901 | 101,208 | |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 25.29 | 2,498 | 63,174 | 30,836 | |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 69.95 | 7,990 | 558,901 | 70,832 | 78.8 K to 70.8 K (-10.14 %) |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 68.10 | 21,141 | 1,439,702 | 78,822 | 100 K to 78.8 K (-21.15 %) |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 20.76 | 26,633 | 552,901 | 99,963 | 73.3 K to 100 K (+36.32 %) |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 25.29 | 2,498 | 63,174 | 73,330 | 70.8 K to 73.3 K (+3.53 %) |
| Dec 20 2017 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 44.96 | 1,816 | 81,647 | 70,832 | 72.6 K to 70.8 K (-2.50 %) |
| Nov 09 2017 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Payment of Exercise | F | 55.98 | 684 | 38,290 | 72,648 | 73.3 K to 72.6 K (-0.93 %) |
| Nov 03 2017 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 25.29 | 6,666 | 168,583 | 33,334 | |
| Nov 03 2017 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 54.95 | 6,666 | 366,297 | 73,332 | 80 K to 73.3 K (-8.33 %) |
| Nov 03 2017 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 25.29 | 6,666 | 168,583 | 79,998 | 73.3 K to 80 K (+9.09 %) |
| Oct 20 2017 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Grant | A | 0.00 | 35,893 | 0 | 73,332 | 37.4 K to 73.3 K (+95.87 %) |
| Sep 14 2017 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 44.95 | 12,850 | 577,608 | 37,439 | 50.3 K to 37.4 K (-25.55 %) |
| Aug 31 2017 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 39.95 | 12,869 | 514,117 | 50,289 | 63.2 K to 50.3 K (-20.38 %) |
| Jun 13 2017 | CASC | Cascadian Therapeu ... | Azelby Robert | Director | Option Exercise | A | 0.00 | 13,927 | 0 | 13,927 | |
| Apr 04 2017 | CASC | Cascadian Therapeu ... | Azelby Robert | Director | Option Exercise | A | 0.00 | 12,437 | 0 | 12,437 | |
| Feb 09 2017 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | A | 20.76 | 127,841 | 2,653,979 | 127,841 | |
| Feb 09 2017 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Grant | A | 0.00 | 27,439 | 0 | 63,158 | 35.7 K to 63.2 K (+76.82 %) |
| Nov 10 2016 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | A | 25.29 | 40,000 | 1,011,600 | 40,000 | |
| Nov 10 2016 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 24.14 | 12,921 | 311,848 | 35,719 | 48.6 K to 35.7 K (-26.56 %) |
| Nov 10 2016 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Grant | A | 0.00 | 10,000 | 0 | 48,640 | 38.6 K to 48.6 K (+25.88 %) |
| Nov 02 2015 | JUNO | Juno Therapeutics, ... | Azelby Robert | See Remarks | Option Exercise | A | 51.76 | 200,000 | 10,352,000 | 200,000 | |
| Nov 02 2015 | JUNO | Juno Therapeutics, ... | Azelby Robert | See Remarks | Grant | A | 0.00 | 38,640 | 0 | 38,640 | 0 to 38.6 K |
Page: 1